Literature DB >> 27156192

Design, synthesis, and biological evaluation of substrate-competitive inhibitors of C-terminal Binding Protein (CtBP).

Sudha Korwar1, Benjamin L Morris2, Hardik I Parikh1, Robert A Coover1, Tyler W Doughty3, Ian M Love2, Brendan J Hilbert4, William E Royer4, Glen E Kellogg1, Steven R Grossman5, Keith C Ellis6.   

Abstract

C-terminal Binding Protein (CtBP) is a transcriptional co-regulator that downregulates the expression of many tumor-suppressor genes. Utilizing a crystal structure of CtBP with its substrate 4-methylthio-2-oxobutyric acid (MTOB) and NAD(+) as a guide, we have designed, synthesized, and tested a series of small molecule inhibitors of CtBP. From our first round of compounds, we identified 2-(hydroxyimino)-3-phenylpropanoic acid as a potent CtBP inhibitor (IC50=0.24μM). A structure-activity relationship study of this compound further identified the 4-chloro- (IC50=0.18μM) and 3-chloro- (IC50=0.17μM) analogues as additional potent CtBP inhibitors. Evaluation of the hydroxyimine analogues in a short-term cell growth/viability assay showed that the 4-chloro- and 3-chloro-analogues are 2-fold and 4-fold more potent, respectively, than the MTOB control. A functional cellular assay using a CtBP-specific transcriptional readout revealed that the 4-chloro- and 3-chloro-hydroxyimine analogues were able to block CtBP transcriptional repression activity. This data suggests that substrate-competitive inhibition of CtBP dehydrogenase activity is a potential mechanism to reactivate tumor-suppressor gene expression as a therapeutic strategy for cancer.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  C-terminal Binding Protein; CtBP; Dehydrogenase; Hydroxyimine; MTOB; Oxime; Transcriptional co-repressor; Tumor suppressor gene

Mesh:

Substances:

Year:  2016        PMID: 27156192      PMCID: PMC4993153          DOI: 10.1016/j.bmc.2016.04.037

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  27 in total

1.  Coordinated histone modifications mediated by a CtBP co-repressor complex.

Authors:  Yujiang Shi; Jun-ichi Sawada; Guangchao Sui; El Bachir Affar; Johnathan R Whetstine; Fei Lan; Hidesato Ogawa; Margaret Po-Shan Luke; Yoshihiro Nakatani; Yang Shi
Journal:  Nature       Date:  2003-04-17       Impact factor: 49.962

2.  Crystal structures of human CtBP in complex with substrate MTOB reveal active site features useful for inhibitor design.

Authors:  Brendan J Hilbert; Steven R Grossman; Celia A Schiffer; William E Royer
Journal:  FEBS Lett       Date:  2014-03-19       Impact factor: 4.124

3.  Structure-guided design of a high affinity inhibitor to human CtBP.

Authors:  Brendan J Hilbert; Benjamin L Morris; Keith C Ellis; Janet L Paulsen; Celia A Schiffer; Steven R Grossman; William E Royer
Journal:  ACS Chem Biol       Date:  2015-01-30       Impact factor: 5.100

4.  C-terminal-binding protein corepresses epithelial and proapoptotic gene expression programs.

Authors:  Madeleine Grooteclaes; Quinn Deveraux; Jeffrey Hildebrand; Qinghong Zhang; Richard H Goodman; Steven M Frisch
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-03       Impact factor: 11.205

5.  Redox sensor CtBP mediates hypoxia-induced tumor cell migration.

Authors:  Qinghong Zhang; Su-Yan Wang; Amanda C Nottke; Jonathan V Rocheleau; David W Piston; Richard H Goodman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-01       Impact factor: 11.205

6.  Role of NAD binding and catalytic residues in the C-terminal binding protein corepressor.

Authors:  Priya Mani-Telang; Montserrat Sutrias-Grau; Geoffrey Williams; David N Arnosti
Journal:  FEBS Lett       Date:  2007-10-12       Impact factor: 4.124

7.  p19Arf inhibits the invasion of hepatocellular carcinoma cells by binding to C-terminal binding protein.

Authors:  Ya-Wen Chen; Seema Paliwal; Kyle Draheim; Steven R Grossman; Brian C Lewis
Journal:  Cancer Res       Date:  2008-01-15       Impact factor: 12.701

8.  The alternative reading frame tumor suppressor antagonizes hypoxia-induced cancer cell migration via interaction with the COOH-terminal binding protein corepressor.

Authors:  Seema Paliwal; Ramesh C Kovi; Bharath Nath; Ya-Wen Chen; Brian C Lewis; Steven R Grossman
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

9.  An ARF/CtBP2 complex regulates BH3-only gene expression and p53-independent apoptosis.

Authors:  R C Kovi; S Paliwal; S Pande; S R Grossman
Journal:  Cell Death Differ       Date:  2009-10-02       Impact factor: 15.828

10.  The CtBP2 co-repressor is regulated by NADH-dependent dimerization and possesses a novel N-terminal repression domain.

Authors:  Sharon S C Thio; Joseph V Bonventre; Stephen I-Hong Hsu
Journal:  Nucleic Acids Res       Date:  2004-03-22       Impact factor: 16.971

View more
  10 in total

1.  Active-Site Tryptophan, the Target of Antineoplastic C-Terminal Binding Protein Inhibitors, Mediates Inhibitor Disruption of CtBP Oligomerization and Transcription Coregulatory Activities.

Authors:  M Michael Dcona; Priyadarshan K Damle; Francisco Zarate-Perez; Benjamin L Morris; Zaid Nawaz; Michael J Dennis; Xiaoyan Deng; Sudha Korwar; Sahib J Singh; Keith C Ellis; William E Royer; Dipankar Bandyopadhyay; Carlos Escalante; Steven R Grossman
Journal:  Mol Pharmacol       Date:  2019-04-29       Impact factor: 4.436

2.  Transforming activity and therapeutic targeting of C-terminal-binding protein 2 in Apc-mutated neoplasia.

Authors:  E T Sumner; A T Chawla; A D Cororaton; J E Koblinski; R C Kovi; I M Love; B B Szomju; S Korwar; K C Ellis; S R Grossman
Journal:  Oncogene       Date:  2017-04-17       Impact factor: 9.867

Review 3.  CtBP- an emerging oncogene and novel small molecule drug target: Advances in the understanding of its oncogenic action and identification of therapeutic inhibitors.

Authors:  M Michael Dcona; Benjamin L Morris; Keith C Ellis; Steven R Grossman
Journal:  Cancer Biol Ther       Date:  2017-05-22       Impact factor: 4.742

4.  CPP-E1A fusion peptides inhibit CtBP-mediated transcriptional repression.

Authors:  Melanie A Blevins; Caiguo Zhang; Lingdi Zhang; Hong Li; Xueni Li; David A Norris; Mingxia Huang; Rui Zhao
Journal:  Mol Oncol       Date:  2018-06-23       Impact factor: 6.603

5.  An intestinal stem cell niche in Apc mutated neoplasia targetable by CtBP inhibition.

Authors:  Ayesha T Chawla; Agnes D Cororaton; Michael O Idowu; Priyadarshan K Damle; Barbara Szomju; Keith C Ellis; Bhaumik B Patel; Steven R Grossman
Journal:  Oncotarget       Date:  2018-08-21

6.  Epigenetic re-wiring of breast cancer by pharmacological targeting of C-terminal binding protein.

Authors:  Jung S Byun; Samson Park; Dae Ik Yi; Jee-Hye Shin; Sara Gil Hernandez; Stephen M Hewitt; Marc C Nicklaus; Megan L Peach; Laura Guasch; Binwu Tang; Lalage M Wakefield; Tingfen Yan; Ambar Caban; Alana Jones; Mohamed Kabbout; Nasreen Vohra; Anna María Nápoles; Sandeep Singhal; Ryan Yancey; Adriana De Siervi; Kevin Gardner
Journal:  Cell Death Dis       Date:  2019-09-18       Impact factor: 8.469

7.  CtBP-a targetable dependency for tumor-initiating cell activity and metastasis in pancreatic adenocarcinoma.

Authors:  Ayesha T Chawla; Kranthi Kumar Chougoni; Prashant J Joshi; Agnes D Cororaton; Patrick Memari; John C Stansfield; Haemin Park; Rashmi Seth; Barbara Szomju; Adam P Sima; Michael O Idowu; Keith C Ellis; Steven R Grossman
Journal:  Oncogenesis       Date:  2019-10-04       Impact factor: 7.485

8.  Epstein-Barr virus nuclear antigen 3C (EBNA3C) interacts with the metabolism sensing C-terminal binding protein (CtBP) repressor to upregulate host genes.

Authors:  Makoto Ohashi; Mitchell Hayes; Kyle McChesney; Eric Johannsen
Journal:  PLoS Pathog       Date:  2021-03-15       Impact factor: 6.823

Review 9.  The transrepression and transactivation roles of CtBPs in the pathogenesis of different diseases.

Authors:  Zhi Chen
Journal:  J Mol Med (Berl)       Date:  2021-07-01       Impact factor: 4.599

10.  CtBP determines ovarian cancer cell fate through repression of death receptors.

Authors:  Boxiao Ding; Fang Yuan; Priyadarshan K Damle; Larisa Litovchick; Ronny Drapkin; Steven R Grossman
Journal:  Cell Death Dis       Date:  2020-04-24       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.